News und Analysen
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Takeda schließt Verkauf ausgewählter OTC- und nicht zum Kerngeschäft gehörender Assets an Acino ab
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) meldete heute den Abschluss des bereits angekündigten Verkaufs eines Portfolios ausgewählter, frei verkäuflicher
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)